↓ Skip to main content

B cell regulation of the anti-tumor response and role in carcinogenesis

Overview of attention for article published in Journal for Immunotherapy of Cancer, July 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

3 tweeters
1 patent


155 Dimensions

Readers on

292 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
B cell regulation of the anti-tumor response and role in carcinogenesis
Published in
Journal for Immunotherapy of Cancer, July 2016
DOI 10.1186/s40425-016-0145-x
Pubmed ID

Marc Schwartz, Yu Zhang, Joseph D. Rosenblatt


The balance between immune effector cells such as T cells and natural killer cells, and immunosuppressive Treg cells, dendritic, myeloid and monocytic sub-populations in the tumor microenvironment acts to calibrate the immune response to malignant cells. Accumulating evidence is pointing to a role for B cells in modulating the immune response to both solid tumors and hematologic cancer. Evidence from murine autoimmune models has defined B regulatory cell (Breg) subsets that express cytokines such as IL-10, TGF-β, and/or express immune regulatory ligands such as PD-L1, which can suppress T cell and/or natural killer cell responses. Multiple murine tumor models exhibit decreased tumor growth in B cell deficient or B cell depleted mice. In several of these models, B cells inhibit T cell mediated tumor immunity and/or facilitate conversion of T cells to CD4(+)CD25(+)FoxP3(+) T regs, which act to attenuate the innate and/or adaptive antitumor immune response. Mechanisms of suppression include the acquisition of inhibitory ligand expression, and phosphorylation of Stat3, and induction of IL-10 and TGF-β, resulting in a Breg phenotype. Breg suppressive activity may affect diverse cell subtypes, including T effector cells, NK cells, myeloid derived suppressor cells (MDSC) and/or tumor associated macrophages. B cells may also directly promote tumorigenesis through recruitment of inflammatory cells, and upregulation of pro-angiogenic genes and pro-metastatic collagenases. Breg infiltration has now been identified in a variety of solid tumor malignancies including but not limited to ovarian, gastric, non-small cell lung cancer, pancreatic, esophageal, head and neck, and hepatocellular carcinomas. Increasing evidence suggests that recruitment of B cells and acquisition of suppressive activity within the tumor bed may be an important mechanism through which B cells may modulate innate and/or adaptive anti-tumor immunity. B cell depletion in the clinic using anti-CD20 antibodies and/or inhibitors of BTK and/or other signaling pathways, may be a useful strategy for augmenting the anti-tumor immune response.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 292 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
United States 1 <1%
Sweden 1 <1%
Unknown 289 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 49 17%
Student > Master 46 16%
Student > Ph. D. Student 40 14%
Student > Bachelor 34 12%
Student > Doctoral Student 17 6%
Other 47 16%
Unknown 59 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 68 23%
Medicine and Dentistry 51 17%
Agricultural and Biological Sciences 43 15%
Immunology and Microbiology 40 14%
Pharmacology, Toxicology and Pharmaceutical Science 4 1%
Other 19 7%
Unknown 67 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2022.
All research outputs
of 21,991,334 outputs
Outputs from Journal for Immunotherapy of Cancer
of 2,709 outputs
Outputs of similar age
of 281,088 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
of 1 outputs
Altmetric has tracked 21,991,334 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,709 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,088 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them